ES2426445T3 - Forma de dosificación oral sólida que contiene un potenciador - Google Patents

Forma de dosificación oral sólida que contiene un potenciador Download PDF

Info

Publication number: ES2426445T3
Authority: ES; Spain
Prior art keywords: dosage form; enhancer; tablets; tablet; sodium
Prior art date: 2006-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07755266T

Other languages

English (en)

Spanish (es)

Inventor

Thomas W. Leonard

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merrion Research Ill Ltd

Original Assignee

Merrion Research Ill Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-07

Filing date

2007-04-09

Publication date

2013-10-23

2007-04-09 Application filed by Merrion Research Ill Ltd filed Critical Merrion Research Ill Ltd

2013-10-23 Application granted granted Critical

2013-10-23 Publication of ES2426445T3 publication Critical patent/ES2426445T3/es

Status Active legal-status Critical Current

2027-04-09 Anticipated expiration legal-status Critical

Links

239000003623 enhancer Substances 0.000 title claims abstract description 132
239000007787 solid Substances 0.000 title claims abstract description 41
239000006186 oral dosage form Substances 0.000 title claims abstract description 38
239000003814 drug Substances 0.000 claims abstract description 88
229940079593 drug Drugs 0.000 claims abstract description 87
239000000203 mixture Substances 0.000 claims abstract description 60
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims abstract description 31
239000002775 capsule Substances 0.000 claims abstract description 30
150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 30
229960004276 zoledronic acid Drugs 0.000 claims abstract description 22
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 19
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 15
210000000936 intestine Anatomy 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
239000003826 tablet Substances 0.000 claims description 169
239000002552 dosage form Substances 0.000 claims description 63
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims description 63
238000011282 treatment Methods 0.000 claims description 62
230000003111 delayed effect Effects 0.000 claims description 19
159000000000 sodium salts Chemical group 0.000 claims description 10
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical group [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 9
239000002662 enteric coated tablet Substances 0.000 claims description 8
229960005480 sodium caprylate Drugs 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims description 6
208000001132 Osteoporosis Diseases 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 4
229940082004 sodium laurate Drugs 0.000 claims description 4
206010005949 Bone cancer Diseases 0.000 claims description 2
208000018084 Bone neoplasm Diseases 0.000 claims description 2
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 111
229940062527 alendronate Drugs 0.000 description 81
229920000669 heparin Polymers 0.000 description 74
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 67
239000003055 low molecular weight heparin Substances 0.000 description 49
229940127215 low-molecular weight heparin Drugs 0.000 description 49
229960002897 heparin Drugs 0.000 description 47
239000000243 solution Substances 0.000 description 42
230000000052 comparative effect Effects 0.000 description 33
238000010521 absorption reaction Methods 0.000 description 31
230000000694 effects Effects 0.000 description 30
229940001490 fosamax Drugs 0.000 description 29
229940122361 Bisphosphonate Drugs 0.000 description 26
150000004663 bisphosphonates Chemical class 0.000 description 26
230000004044 response Effects 0.000 description 24
-1 fatty acid ester Chemical class 0.000 description 22
239000008187 granular material Substances 0.000 description 22
238000013268 sustained release Methods 0.000 description 22
239000012730 sustained-release form Substances 0.000 description 22
238000012360 testing method Methods 0.000 description 22
210000004027 cell Anatomy 0.000 description 21
239000010410 layer Substances 0.000 description 20
230000001186 cumulative effect Effects 0.000 description 19
238000004519 manufacturing process Methods 0.000 description 19
210000002700 urine Anatomy 0.000 description 19
241000282472 Canis lupus familiaris Species 0.000 description 18
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 17
238000000576 coating method Methods 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
235000013305 food Nutrition 0.000 description 15
238000000034 method Methods 0.000 description 15
108010000817 Leuprolide Proteins 0.000 description 14
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 14
229960004338 leuprorelin Drugs 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000011734 sodium Substances 0.000 description 14
229910052708 sodium Inorganic materials 0.000 description 14
230000009885 systemic effect Effects 0.000 description 14
230000032258 transport Effects 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
239000011248 coating agent Substances 0.000 description 13
238000009472 formulation Methods 0.000 description 13
239000000463 material Substances 0.000 description 13
229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
150000002148 esters Chemical class 0.000 description 12
229960004762 parnaparin Drugs 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
239000012981 Hank's balanced salt solution Substances 0.000 description 10
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 10
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 10
102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 10
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
238000013270 controlled release Methods 0.000 description 10
235000020828 fasting Nutrition 0.000 description 10
239000012729 immediate-release (IR) formulation Substances 0.000 description 10
239000005022 packaging material Substances 0.000 description 10
229920000642 polymer Polymers 0.000 description 10
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 10
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
229930195725 Mannitol Natural products 0.000 description 9
241000700159 Rattus Species 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
230000029142 excretion Effects 0.000 description 9
239000012728 immediate-release (IR) tablet Substances 0.000 description 9
239000000594 mannitol Substances 0.000 description 9
235000010355 mannitol Nutrition 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
238000007920 subcutaneous administration Methods 0.000 description 9
239000007916 tablet composition Substances 0.000 description 9
229940002005 zometa Drugs 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
238000004090 dissolution Methods 0.000 description 8
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
238000011552 rat model Methods 0.000 description 8
238000000540 analysis of variance Methods 0.000 description 7
239000007950 delayed release tablet Substances 0.000 description 7
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
210000002784 stomach Anatomy 0.000 description 7
230000036325 urinary excretion Effects 0.000 description 7
229920003136 Eudragit® L polymer Polymers 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
235000014113 dietary fatty acids Nutrition 0.000 description 6
239000000194 fatty acid Substances 0.000 description 6
229930195729 fatty acid Natural products 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000011260 co-administration Methods 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
230000037361 pathway Effects 0.000 description 5
239000008188 pellet Substances 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000000523 sample Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000002356 single layer Substances 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
239000008399 tap water Substances 0.000 description 5
235000020679 tap water Nutrition 0.000 description 5
241000282412 Homo Species 0.000 description 4
229920003093 Methocel™ K100 LV Polymers 0.000 description 4
210000001015 abdomen Anatomy 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
239000007884 disintegrant Substances 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
210000004731 jugular vein Anatomy 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000035699 permeability Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
229920003109 sodium starch glycolate Polymers 0.000 description 4
239000008109 sodium starch glycolate Substances 0.000 description 4
229940079832 sodium starch glycolate Drugs 0.000 description 4
239000012085 test solution Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
229910002012 Aerosil® Inorganic materials 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
229920003081 Povidone K 30 Polymers 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
108010004977 Vasopressins Proteins 0.000 description 3
102000002852 Vasopressins Human genes 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000013361 beverage Nutrition 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
235000021152 breakfast Nutrition 0.000 description 3
150000007942 carboxylates Chemical group 0.000 description 3
230000008859 change Effects 0.000 description 3
229940075614 colloidal silicon dioxide Drugs 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
210000001198 duodenum Anatomy 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000001917 fluorescence detection Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
229920001600 hydrophobic polymer Polymers 0.000 description 3
210000004347 intestinal mucosa Anatomy 0.000 description 3
235000014666 liquid concentrate Nutrition 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
238000002483 medication Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
239000002105 nanoparticle Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000004417 polycarbonate Substances 0.000 description 3
239000011253 protective coating Substances 0.000 description 3
238000011002 quantification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
229960003726 vasopressin Drugs 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000006386 Bone Resorption Diseases 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
229920003151 Eudragit® RL polymer Polymers 0.000 description 2
229920003152 Eudragit® RS polymer Polymers 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
108700012941 GNRH1 Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
229920001499 Heparinoid Polymers 0.000 description 2
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
229920003095 Methocel™ K15M Polymers 0.000 description 2
101100504379 Mus musculus Gfral gene Proteins 0.000 description 2
206010030201 Oesophageal ulcer Diseases 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
101710142969 Somatoliberin Proteins 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 2
MKPXGEVFQSIKGE-UHFFFAOYSA-N [Mg].[Si] Chemical compound [Mg].[Si] MKPXGEVFQSIKGE-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000024279 bone resorption Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
229960002286 clodronic acid Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
208000028299 esophageal disease Diseases 0.000 description 2
208000019064 esophageal ulcer Diseases 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
229940009626 etidronate Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000013265 extended release Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
239000002554 heparinoid Substances 0.000 description 2
229940025770 heparinoids Drugs 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
229940015872 ibandronate Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229950006971 incadronic acid Drugs 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007794 irritation Effects 0.000 description 2
229960004184 ketamine hydrochloride Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 2
229950011129 minodronic acid Drugs 0.000 description 2
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 2
229950010733 neridronic acid Drugs 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
229940046231 pamidronate Drugs 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
229920000193 polymethacrylate Polymers 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
210000001187 pylorus Anatomy 0.000 description 2
239000012088 reference solution Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229940089617 risedronate Drugs 0.000 description 2
239000012488 sample solution Substances 0.000 description 2
238000005070 sampling Methods 0.000 description 2
LTOCMXUTASYUOC-UHFFFAOYSA-M sodium;nonanoate Chemical compound [Na+].CCCCCCCCC([O-])=O LTOCMXUTASYUOC-UHFFFAOYSA-M 0.000 description 2
ZOOPHYLANWVUDY-UHFFFAOYSA-M sodium;undecanoate Chemical compound [Na+].CCCCCCCCCCC([O-])=O ZOOPHYLANWVUDY-UHFFFAOYSA-M 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940019375 tiludronate Drugs 0.000 description 2
230000031998 transcytosis Effects 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
239000000341 volatile oil Substances 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 1
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
244000024675 Eruca sativa Species 0.000 description 1
235000014755 Eruca sativa Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010005714 Interferon beta-1b Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
206010053961 Mitochondrial toxicity Diseases 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
231100000987 absorbed dose Toxicity 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960001946 acepromazine maleate Drugs 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229960004343 alendronic acid Drugs 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940127090 anticoagulant agent Drugs 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
229960003002 atipamezole Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
229940021459 betaseron Drugs 0.000 description 1
208000016738 bone Paget disease Diseases 0.000 description 1
230000037176 bone building Effects 0.000 description 1
230000037182 bone density Effects 0.000 description 1
230000008416 bone turnover Effects 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229940069978 calcium supplement Drugs 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000007799 cork Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
238000013461 design Methods 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000001761 ethyl methyl cellulose Substances 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000556 factor analysis Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
235000020937 fasting conditions Nutrition 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
IAVGMIBOMLTFSU-UHFFFAOYSA-L magnesium dioxosilane octadecanoate Chemical compound [Mg+2].O=[Si]=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O IAVGMIBOMLTFSU-UHFFFAOYSA-L 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
229960002140 medetomidine Drugs 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
231100000296 mitochondrial toxicity Toxicity 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
230000009057 passive transport Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
239000011537 solubilization buffer Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
229960004532 somatropin Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000013179 statistical model Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012353 t test Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
230000018889 transepithelial transport Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000005591 trimellitate group Chemical group 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES07755266T 2006-04-07 2007-04-09 Forma de dosificación oral sólida que contiene un potenciador Active ES2426445T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79123106P	2006-04-07	2006-04-07
US791231P		2006-04-07
PCT/US2007/008935 WO2007117706A2 (en)	2006-04-07	2007-04-09	Solid oral dosage form containing an enhancer

Publications (1)

Publication Number	Publication Date
ES2426445T3 true ES2426445T3 (es)	2013-10-23

Family

ID=38581701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07755266T Active ES2426445T3 (es)	2006-04-07	2007-04-09	Forma de dosificación oral sólida que contiene un potenciador

Country Status (13)

Country	Link
US (3)	US7704977B2 (pt)
EP (2)	EP2526950A1 (pt)
JP (3)	JP5450052B2 (pt)
KR (1)	KR101191322B1 (pt)
CN (2)	CN105232482A (pt)
AU (1)	AU2007235251B2 (pt)
BR (1)	BRPI0710503A2 (pt)
CA (1)	CA2648594C (pt)
ES (1)	ES2426445T3 (pt)
IL (1)	IL194277A (pt)
MX (1)	MX2008012678A (pt)
RU (1)	RU2437662C2 (pt)
WO (1)	WO2007117706A2 (pt)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658938B2 (en) *	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US20070219131A1 (en) *	2004-04-15	2007-09-20	Ben-Sasson Shmuel A	Compositions capable of facilitating penetration across a biological barrier
CA2563533C (en) *	2004-04-15	2013-10-01	Shmuel A. Ben-Sasson	Compositions capable of facilitating penetration across a biological barrier
US20080287400A1 (en) *	2004-05-24	2008-11-20	Richard John Dansereau	Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en)	2004-05-24	2010-01-12	The Procter & Gamble Company	Dosage forms of bisphosphonates
US20080286359A1 (en) *	2004-05-24	2008-11-20	Richard John Dansereau	Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) *	2004-05-24	2010-01-12	The Procter & Gamble Company	Dosage forms of risedronate
BRPI0710503A2 (pt) *	2006-04-07	2011-08-16	Merrion Res Iii Ltd	uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007146234A2 (en) *	2006-06-09	2007-12-21	Merrion Research Ii Limited	Solid oral dosage form containing an enhancer
US20090280169A1 (en) *	2008-05-07	2009-11-12	Merrion Research Iii Limited	Compositions of peptides and processes of preparation thereof
RU2678833C2 (ru) *	2008-09-17	2019-02-04	Киазма Инк.	Фармацевтические композиции и соответствующие способы доставки
PL226261B1 (pl) *	2008-12-31	2017-07-31	Univ Jagiellonski	Kompozycja do przedłużonego uwalniania heparyny i zastosowanie żelu alginian-hydroksypropyloceluloza do przedłużonego uwalniania heparyny
TWI480286B (zh) *	2009-02-25	2015-04-11	Merrion Res Iii Ltd	雙膦酸鹽類組合物及藥物遞送
EP2405934B1 (en)	2009-03-12	2014-03-26	Nordic Bioscience A/S	Treatment of diabetes and metabolic syndrome
US9169279B2 (en)	2009-07-31	2015-10-27	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
KR101813728B1 (ko) *	2009-07-31	2017-12-29	그뤼넨탈 게엠베하	결정화 방법 및 생체이용률
US20160016982A1 (en)	2009-07-31	2016-01-21	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
DK2473172T3 (en) *	2009-09-01	2015-06-15	Univ Duke	BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
FR2954320B1 (fr) *	2009-12-17	2012-06-15	Cll Pharma	Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en)	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en)	2010-11-24	2012-05-31	Thar Pharmaceuticals, Inc.	Novel crystalline forms
AU2011341637A1 (en) *	2010-12-15	2013-06-20	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
EP2661273A4 (en)	2011-01-07	2014-06-04	Merrion Res Iii Ltd	IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
AU2012241894B2 (en)	2011-04-12	2015-12-03	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
FR2975300B1 (fr) *	2011-05-19	2013-06-07	Thierry Breul	Composition pharmaceutique a biodisponibilite amelioree
SI3095484T1 (en)	2011-11-02	2018-08-31	Keybioscience Ag	Calcitonin mimetics for the treatment of diseases and disorders
CA2854175A1 (en)	2011-11-02	2013-05-10	Keybioscience Ag	Peptide analogs for treating diseases and disorders
HUE064694T2 (hu)	2012-03-22	2024-04-28	Novo Nordisk As	Továbbítószert tartalmazó készítmények és elõállításuk
KR102072202B1 (ko)	2012-03-22	2020-01-31	노보 노르디스크 에이/에스	Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es)	2012-03-22	2019-06-03	Novo Nordisk As	Composiciones que comprenden un agente de suministro y su preparación
US8802658B2 (en)	2012-05-14	2014-08-12	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9655908B2 (en)	2012-05-14	2017-05-23	Antecip Bioventures Ii Llc	Neridronic acid molecular complex for treating complex regional pain syndrome
US10080765B2 (en)	2012-05-14	2018-09-25	Antecip Bioventures Ii Llc	Neridronic acid for treating complex regional pain syndrome
US10028908B2 (en)	2012-05-14	2018-07-24	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9700570B2 (en)	2014-05-27	2017-07-11	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en)	2012-05-14	2018-04-24	Antecip Bioventures Ii Llc	Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9956234B2 (en)	2012-05-14	2018-05-01	Antecip Bioventures Ii Llc	Osteoclast inhibitors for joint conditions
US9895383B2 (en)	2012-05-14	2018-02-20	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9427403B2 (en)	2012-05-14	2016-08-30	Antecip Bioventures Ii Llc	Methods for the safe administration of imidazole or imidazolium compounds
US10092581B2 (en)	2014-05-15	2018-10-09	Antecip Bioventures Ii Llc	Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956237B2 (en)	2012-05-14	2018-05-01	Antecip Bioventures Ii Llc	Osteoclast inhibitors for knee conditions
US9943531B2 (en)	2014-08-08	2018-04-17	Antecip Bioventures Ii Llc	Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9861648B2 (en)	2012-05-14	2018-01-09	Antecip Boiventures Ii Llc	Osteoclast inhibitors for knee conditions
US9707245B2 (en)	2012-05-14	2017-07-18	Antecip Bioventures Ii Llc	Neridronic acid for treating complex regional pain syndrome
US9675626B2 (en)	2012-05-14	2017-06-13	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028969B2 (en)	2012-05-14	2018-07-24	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en)	2012-05-14	2018-08-07	Antecip Bioventures Ii Llc	Neridronic acid for treating arthritis
US9956238B2 (en)	2014-05-15	2018-05-01	Antecip Bioventures Ii Llc	Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10111837B2 (en)	2012-05-14	2018-10-30	Antecip Bioventures Ii Llc	Dosage forms for oral administration of zoledronic acid or related compounds
US9999629B2 (en)	2012-05-14	2018-06-19	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en)	2012-05-14	2019-12-03	Antecip Bioventures Ii Llc	Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413561B2 (en)	2012-05-14	2019-09-17	Antecip Bioventures Ii Llc	Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9694023B2 (en)	2012-05-14	2017-07-04	Antecip Bioventures Ii Llc	Methods for the safe administration of imidazole or imidazolium compounds
US9827256B2 (en)	2014-05-27	2017-11-28	Antecip Bioventures Ii Llc	Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9662343B2 (en)	2012-05-14	2017-05-30	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016445B2 (en)	2012-05-14	2018-07-10	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
PL2849758T3 (pl) *	2012-05-14	2018-08-31	Antecip Bioventures Ii Llc	Kompozycje zawierające kwas zoledronowy lub pokrewne związki do uśmierzania bólu zapalnego i stanów powiązanych
US9616078B2 (en)	2012-05-14	2017-04-11	Antecip Bioventures Ii Llc	Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9925203B2 (en)	2012-05-14	2018-03-27	Antecip Bioventures Ii Llc	Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10350227B2 (en)	2012-05-14	2019-07-16	Antecip Bioventures Ii Llc	Neridronic acid for treating complex regional pain syndrome
US11654152B2 (en)	2012-05-14	2023-05-23	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9770457B2 (en)	2012-05-14	2017-09-26	Antecip Bioventures Ii Llc	Neridronic acid for treating bone marrow lesion
US9717747B2 (en)	2012-05-14	2017-08-01	Antecip Bioventures Ii Llc	Osteoclast inhibitors for knee conditions
US9867840B2 (en)	2014-05-27	2018-01-16	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9211257B2 (en)	2012-05-14	2015-12-15	Antecip Bioventures Ii Llc	Osteoclast inhibitors for knee conditions
US10173986B2 (en)	2012-05-14	2019-01-08	Antecip Bioventures Ii Llc	Methods for the safe administration of imidazole or imidazolium compounds
US10034890B2 (en)	2012-05-14	2018-07-31	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867839B2 (en)	2012-05-14	2018-01-16	Antecip Bioventures Ii Llc	Osteoclast inhibitors for joint conditions
US10463682B2 (en)	2012-05-14	2019-11-05	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9782421B1 (en)	2012-05-14	2017-10-10	Antecip Bioventures Ii Llc	Neridronic acid molecular complex for treating complex regional pain syndrome
US10413560B2 (en)	2012-05-14	2019-09-17	Antecip Bioventures Ii Llc	Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9901589B2 (en)	2012-05-14	2018-02-27	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en)	2012-05-14	2017-10-24	Antecip Bioventures Ii Llc	Neridronic acid for treating pain associated with a joint
US9999628B2 (en)	2012-05-14	2018-06-19	Antecip Bioventures Ii Llc	Neridronic acid for treating complex regional pain syndrome
US10016446B2 (en)	2012-05-14	2018-07-10	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9844559B2 (en)	2012-05-14	2017-12-19	Antecip Bioventures Ii Llc	Neridronic acid for treating bone marrow lesions
US9877977B2 (en)	2012-05-14	2018-01-30	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9820999B2 (en)	2012-05-14	2017-11-21	Antecip Bioventures Ii Llc	Neridronic acid for treating complex regional pain syndrome
US9789128B2 (en)	2012-05-14	2017-10-17	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9289441B2 (en)	2014-08-08	2016-03-22	Antecip Bioventures Ii Llc	Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9707247B2 (en)	2012-05-14	2017-07-18	Antecip Bioventures Ii Llc	Compositions for administration of zoledronic acid or related compounds for treating low back pain
US8865757B1 (en)	2014-05-28	2014-10-21	Antecip Bioventures Ii Llp	Therapeutic compositions comprising imidazole and imidazolium compounds
US9827192B2 (en)	2012-05-14	2017-11-28	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en)	2012-05-14	2017-06-06	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en)	2014-05-15	2018-06-26	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
WO2013189988A1 (en)	2012-06-20	2013-12-27	Novo Nordisk A/S	Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr)	2013-05-02	2019-02-28	Novo Nordisk As	Oralno doziranje glp-1 jedinjenja
EP3024447A1 (en) *	2013-07-24	2016-06-01	Novo Nordisk A/S	Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
BR112016010643A2 (pt)	2013-11-14	2017-12-05	Keybioscience Ag	peptídeo
US9127069B1 (en)	2014-06-11	2015-09-08	Antecip Bioventures LLC	Compositions comprising rank/rankl antagonists and related compounds for treating pain
WO2016020901A1 (en)	2014-08-07	2016-02-11	Acerta Pharma B.V.	Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
GB201500263D0 (en)	2015-01-08	2015-02-25	Keybioscience Ag	Calcitonin analogues for treating diseases and disorders
JP7211704B2 (ja)	2015-01-29	2023-01-24	ノヴォノルディスクアー／エス	Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
JP6737793B2 (ja) *	2015-01-29	2020-08-12	ノヴォノルディスクアー／エス	錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
SI3253401T1 (sl)	2015-02-03	2025-07-31	Amryt Endo, Inc.	Zdravljenje akromegalije z oralnim oktreotidom
WO2016128972A1 (en)	2015-02-09	2016-08-18	Entera Bio Ltd.	Formulations for oral administration of active agents with controlled absorption profile
WO2017208070A1 (en)	2016-05-31	2017-12-07	Grünenthal GmbH	Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
MX2019001850A (es) *	2016-08-17	2019-05-15	Entera Bio Ltd	Formulaciones para administracion oral de principios activos.
GB201704429D0 (en)	2017-03-21	2017-05-03	Keybioscience Ag	Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en)	2017-05-18	2017-07-05	Keybioscience Ag	Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US11654114B2 (en) *	2017-06-07	2023-05-23	Egy-Nano Pharma, Lp	Oral prolonged drug delivery platforms
AR114353A1 (es)	2018-02-02	2020-08-26	Novo Nordisk As	Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
GB201813677D0 (en)	2018-08-22	2018-10-03	Keybioscience Ag	Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en)	2018-08-22	2018-10-03	Keybioscience Ag	Acylated calcitonin mimetics
CN114729376A (zh)	2019-09-23	2022-07-08	欧米茄治疗公司	用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
AU2020355000A1 (en)	2019-09-23	2022-03-17	Sepia Therapeutics, Inc.	Compositions and methods for modulating apolipoprotein B (APOB) gene expression
WO2021183720A1 (en)	2020-03-11	2021-09-16	Omega Therapeutics, Inc.	Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods
WO2023283359A2 (en)	2021-07-07	2023-01-12	Omega Therapeutics, Inc.	Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
EP4396162A4 (en)	2021-09-03	2025-11-12	Alexander Shulgin Res Institute Inc	ASYMMETRIC ALLYL TRYPTAMINES
US12465578B2 (en)	2021-09-25	2025-11-11	Alexander Shulgin Research Institute, Inc.	Substituted alpha-ethyl phenylalkylamines
CN113908155A (zh) *	2021-10-29	2022-01-11	湖南师范大学	脂肪酸钠盐辅助靶向药Sorafenib抗肝癌的一种药物组合物
EP4716741A2 (en)	2023-05-23	2026-04-01	Flagship Labs 114, Inc.	Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
CN122070127A (zh) *	2023-10-25	2026-05-19	默沙东有限责任公司	中链脂肪酸团聚结晶盐
US12653834B1 (en)	2025-05-29	2026-06-16	Ambros Therapeutics, Inc.	Methods of selectively treating complex regional pain syndrome type I (CRPS-I) using bisphosphonate derivatives

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB953626A (en)	1961-04-25	1964-03-25	Meito Sangyo Kk	Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
US4525339A (en)	1982-10-15	1985-06-25	Hoffmann-La Roche Inc.	Enteric coated oral dosage form
JPS5973600A (ja)	1982-10-19	1984-04-25	Okayasu Shoten:Kk	排卵誘発剤
WO1984004674A1 (en)	1983-05-31	1984-12-06	Jang Choong Gook	Dry direct compression compositions for controlled release dosage forms
DE3331009A1 (de)	1983-08-27	1985-03-14	Basf Ag, 6700 Ludwigshafen	Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4590062A (en) *	1984-04-16	1986-05-20	Tech Trade Corp.	Dry direct compression compositions for controlled release dosage forms
US4654155A (en) *	1985-03-29	1987-03-31	Reynolds Metals Company	Microemulsion lubricant
US5288497A (en)	1985-05-01	1994-02-22	The University Of Utah	Compositions of oral dissolvable medicaments
US4764375A (en) *	1985-09-11	1988-08-16	Kv Pharmaceutical Company	Sachet drug delivery system
US4786508A (en) *	1986-05-30	1988-11-22	Warner-Lambert Company	Coated dosage forms
US4789547A (en)	1987-06-17	1988-12-06	Warner-Lambert Company	Transdermal matrix system
IL87710A (en) *	1987-09-18	1992-06-21	Ciba Geigy Ag	Covered floating retard form for controlled release in gastric juice
US5221734A (en)	1987-10-01	1993-06-22	Ciba-Geigy Corporation	Process for preparing a polypeptide growth factor for milk
GB2212396A (en)	1987-12-18	1989-07-26	Procter & Gamble	Dietary supplement comprising calcium and delayed release coated iron
NZ228285A (en)	1988-03-11	1991-08-27	Teikoku Seiyaku Kk	Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5169933A (en)	1988-08-15	1992-12-08	Neorx Corporation	Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5190748A (en)	1988-11-22	1993-03-02	Hoffmann-La Roche Inc.	Absorption enhancement of antibiotics
ZA898331B (en)	1988-11-22	1990-07-25	Hoffmann La Roche	Pharmaceutical compositions
IL92537A (en)	1988-12-15	1994-04-12	Riker Laboratories Inc	Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
GB2244015B (en)	1990-03-14	1993-10-27	Hadley Sections Limited	Tube and method of forming same
JPH03275633A (ja)	1990-03-23	1991-12-06	Teikoku Seiyaku Co Ltd	生理活性ポリペプチドの吸収促進剤
US5541155A (en)	1994-04-22	1996-07-30	Emisphere Technologies, Inc.	Acids and acid salts and their use in delivery systems
JPH04149126A (ja)	1990-10-09	1992-05-22	Mitsubishi Kasei Corp	経粘膜投与用医薬組成物
US5110606A (en) *	1990-11-13	1992-05-05	Affinity Biotech, Inc.	Non-aqueous microemulsions for drug delivery
IT1245761B (it)	1991-01-30	1994-10-14	Alfa Wassermann Spa	Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
US5744450A (en) *	1991-03-14	1998-04-28	The Salk Institute For Biological Studies	GnRH analogs
US5688761A (en) *	1991-04-19	1997-11-18	Lds Technologies, Inc.	Convertible microemulsion formulations
DE69229779T2 (de) *	1991-04-19	1999-12-23	Lds Technologies, Inc.	Konvertierbare mikroemulsionsverbindungen
CA2070061C (en)	1991-06-07	2004-02-10	Shigeyuki Takama	Physiologically active polypeptide-containing pharmaceutical composition
CZ282760B6 (cs)	1991-11-22	1997-09-17	Procter And Gamble Pharmaceuticals, Inc.	Risedronátové prostředky se zpožděným uvolňováním
US5229130A (en)	1991-12-20	1993-07-20	Cygnus Therapeutics Systems	Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
SE501389C2 (sv)	1992-04-24	1995-01-30	Leiras Oy	Farmaceutiskt preparat och förfarande för dess framställning
DE4317458A1 (de) *	1992-06-11	1993-12-16	Bayer Ag	Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
JP3190441B2 (ja)	1992-07-20	2001-07-23	エーザイ株式会社	塩酸アゼラスチンを含有する安定な製剤
RU2068689C1 (ru)	1992-09-24	1996-11-10	Товарищество с ограниченной ответственностью "Лекрон"	Способ получения таблеток парацетамола
KR0157280B1 (ko)	1992-11-06	1998-11-16	나까토미 히로타카	하부소화관 방출성의 경구의약제제
JPH06192107A (ja)	1992-12-25	1994-07-12	Sanwa Kagaku Kenkyusho Co Ltd	グリチルリチン経口剤
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
SE9302135D0 (sv)	1993-06-18	1993-06-18	Kabi Pharmacia Ab	New pharmaceutical composition
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
ES2068762B1 (es)	1993-07-21	1995-12-01	Lipotec Sa	Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
JPH09510182A (ja) *	1993-11-17	1997-10-14	エルディーエス・テクノロジーズ・インコーポレーテッド	カプセル封入されたドラッグデリバリー用透明液
DE69530973T2 (de)	1994-02-16	2004-05-19	Abbott Laboratories, Abbott Park	Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen
US5506207A (en) *	1994-03-18	1996-04-09	The Salk Institute For Biological Studies	GNRH antagonists XIII
IL110024A (en)	1994-06-15	1998-04-05	Yissum Res Dev Co	Controlled release oral drug delivery system containing hydrogel- forming polymer
US5639469A (en) *	1994-06-15	1997-06-17	Minnesota Mining And Manufacturing Company	Transmucosal delivery system
GB9414318D0 (en)	1994-07-15	1994-09-07	Dowelanco Ltd	Preparation of aqueous emulsions
AU713461B2 (en)	1994-11-17	1999-12-02	Toray Industries, Inc.	Preparation for percutaneous absorption
US6524557B1 (en) *	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
US5650386A (en)	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
KR19990014865A (ko)	1995-05-17	1999-02-25	피터 이. 브래이브맨	소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5631347A (en)	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
US6572879B1 (en)	1995-06-07	2003-06-03	Alza Corporation	Formulations for transdermal delivery of pergolide
GB9516268D0 (en)	1995-08-08	1995-10-11	Danbiosyst Uk	Compositiion for enhanced uptake of polar drugs from the colon
US5766620A (en)	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5807983A (en) *	1995-12-28	1998-09-15	The Salk Institute For Biological Studies	GNRH antagonist betides
DE69726879T2 (de)	1996-05-17	2004-10-14	Merck & Co., Inc.	Biphosphonat-formulierung mit brausewirkung
US6147088A (en)	1996-05-20	2000-11-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
CA2254769A1 (en)	1996-05-20	1997-11-27	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US6150522A (en)	1996-05-20	2000-11-21	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US5932547A (en) *	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US5916582A (en) *	1996-07-03	1999-06-29	Alza Corporation	Aqueous formulations of peptides
GB9614235D0 (en)	1996-07-06	1996-09-04	Danbiosyst Uk	Composition for enhanced uptake of polar drugs from mucosal surfaces
US5912009A (en)	1996-10-30	1999-06-15	Theratech, Inc.	Fatty acid esters of glycolic acid and its salts
US5821230A (en) *	1997-04-11	1998-10-13	Ferring Bv	GnRH antagonist decapeptides
US5925730A (en) *	1997-04-11	1999-07-20	Ferring Bv	GnRH antagonists
US6156772A (en)	1997-06-05	2000-12-05	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US6004984A (en)	1997-06-05	1999-12-21	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US5981550A (en) *	1997-06-05	1999-11-09	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US6156767A (en)	1997-06-05	2000-12-05	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
IL121269A0 (en)	1997-07-09	1998-01-04	Dpharm Ltd	Compositions and methods for reversibly increasing permeability of biomembranes
IL121268A0 (en)	1997-07-09	1998-01-04	Dpharm Ltd	Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
JP4181232B2 (ja)	1997-07-18	2008-11-12	帝國製薬株式会社	ジクロフェナクナトリウム含有油性外用貼付製剤
US6015801A (en) *	1997-07-22	2000-01-18	Merck & Co., Inc.	Method for inhibiting bone resorption
SE9703691D0 (sv) *	1997-10-10	1997-10-10	Astra Ab	Pharmaceutical compositions
US6017944A (en) *	1997-10-28	2000-01-25	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
KR20010041696A (ko)	1998-03-11	2001-05-25	그레랑 파마수티컬 가부시키가이샤	발포성 장용(腸溶) 제제
US6025366A (en) *	1998-04-02	2000-02-15	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US5998432A (en)	1998-04-02	1999-12-07	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US6077847A (en) *	1998-04-02	2000-06-20	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US6270804B1 (en)	1998-04-03	2001-08-07	Biovail Technologies Ltd.	Sachet formulations
GB2336311A (en)	1998-04-15	1999-10-20	Merck & Co Inc	Bisphosphonate Dosing Regimen
US6656922B2 (en)	1998-05-28	2003-12-02	Mediplex Corporation, Korea	Oral delivery of macromolecules
JP3853985B2 (ja) *	1998-08-03	2006-12-06	有限会社健康百二十才	鉄イオン含有殺菌液
WO2000022909A2 (en)	1998-10-19	2000-04-27	Biotech Australia Pty. Limited	Systems for oral delivery
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
DE60038097T2 (de)	1999-02-22	2009-02-12	Merrion Research I Ltd.	Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SE9901272D0 (sv) *	1999-04-09	1999-04-09	Astra Ab	New improved formulation
JP2001081031A (ja)	1999-08-30	2001-03-27	Schering Ag	溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
EP1246839B1 (en)	1999-12-08	2004-06-16	Xcyte Therapies, Inc.	Depsipeptide and congeners thereof for use as immunosuppressants
US20020002140A1 (en) *	2000-01-14	2002-01-03	Holick Michael F.	Novel bisphosphonates and uses thereof
WO2001076577A2 (en) *	2000-04-07	2001-10-18	The Board Of Regents Of The University Of Texas System	Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US6468559B1 (en) *	2000-04-28	2002-10-22	Lipocine, Inc.	Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
IT1318539B1 (it)	2000-05-26	2003-08-27	Italfarmaco Spa	Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
CN1141974C (zh) *	2000-06-07	2004-03-17	张昊	结肠定位释放的口服生物制剂
DK1296689T3 (da) *	2000-06-20	2005-11-28	Novartis Ag	Fremgangsmåde til indgivelse af bisphosphonater
WO2002055017A2 (en) *	2000-11-21	2002-07-18	Wake Forest University	Method of treating autoimmune diseases
GB0029111D0 (en)	2000-11-29	2001-01-10	Novartis Ag	Organic compounds
US6379960B1 (en)	2000-12-06	2002-04-30	Isis Pharmaceuticals, Inc.	Antisense modulation of damage-specific DNA binding protein 2, p48 expression
US20020103131A1 (en) *	2001-01-26	2002-08-01	Jacobson Jill D.	Prevention of diabetes by administration of GnRH antagonists
JP2004525110A (ja) *	2001-02-16	2004-08-19	清水製薬株式会社	ムコ多糖類製剤およびその製造法
CA2438848C (en) *	2001-03-01	2011-05-03	Emisphere Technologies, Inc.	Compositions for delivering bisphosphonates
BR0209365A (pt) *	2001-05-02	2004-06-08	Novartis Ag	Usos farmacêuticos de bisfosfonatos
EP1390024A4 (en)	2001-05-11	2010-02-17	Merrion Res Iii Ltd	ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS
JP4381805B2 (ja) *	2001-07-02	2009-12-09	メリオンリサーチスリーリミテッド	生物活性材料の送達
US20030031757A1 (en)	2001-08-03	2003-02-13	Kraft Food Holdings, Inc.	Stable and bioavailable iron fortified beverages
US7098305B2 (en) *	2001-09-06	2006-08-29	Ardana Bioscience Limited	Sustained release of microcrystalline peptide suspensions
DE10157628A1 (de)	2001-11-26	2003-06-12	Zentaris Ag	Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) *	2001-11-27	2007-05-08	Zentaris Gmbh	Injectable solution of an LHRH antagonist
EP1460992B1 (en)	2001-12-03	2009-03-11	Dor Biopharma, Inc.	Stabilized reverse micelle compositions and uses thereof
JP2005516928A (ja) *	2001-12-13	2005-06-09	メルク　エンド　カムパニー　インコーポレーテッド	骨異常のためのビスホスホネート液体製剤
IL162293A0 (en) *	2001-12-19	2005-11-20	Alza Corp	Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US7351800B2 (en)	2002-02-28	2008-04-01	Nipro Corporation	Stabilized albumin preparations
US7148257B2 (en)	2002-03-04	2006-12-12	Merck Hdac Research, Llc	Methods of treating mesothelioma with suberoylanilide hydroxamic acid
BR0308901A (pt) *	2002-05-10	2005-01-04	Hoffmann La Roche	ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US20050080075A1 (en) *	2003-08-25	2005-04-14	Nichols M. James	Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2004273672A1 (en) *	2003-09-19	2005-03-31	Wisconsin Alumni Research Foundation	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
RU2006118801A (ru) *	2003-10-31	2007-12-10	Алза Корпорейшн (Us)	Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
US8987322B2 (en) *	2003-11-04	2015-03-24	Circ Pharma Research And Development Limited	Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE10358525A1 (de)	2003-12-13	2005-07-07	Bayer Healthcare Ag	Endoparasitizide Mittel zur topischen Applikation
AR046773A1 (es)	2003-12-23	2005-12-21	Novartis Ag	Formulaciones farmaceuticas de bisfosfonatos
AU2003290345A1 (en) *	2003-12-24	2005-07-14	Astrazeneca Ab	Pharmaceutical dissolution testing using a non-ionic surfactant
US7606313B2 (en) *	2004-01-15	2009-10-20	Ittiam Systems (P) Ltd.	System, method, and apparatus for error concealment in coded video signals
WO2005072747A1 (ja)	2004-02-02	2005-08-11	Ono Pharmaceutical Co., Ltd.	骨吸収抑制剤
CA2563533C (en) *	2004-04-15	2013-10-01	Shmuel A. Ben-Sasson	Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) *	2004-04-15	2007-09-20	Ben-Sasson Shmuel A	Compositions capable of facilitating penetration across a biological barrier
US20070212395A1 (en) *	2006-03-08	2007-09-13	Allergan, Inc.	Ocular therapy using sirtuin-activating agents
KR20080083068A (ko) *	2004-05-24	2008-09-12	더 프록터 앤드 갬블 캄파니	킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
CA2574085C (en)	2004-07-16	2014-02-11	Oakwood Laboratories, L.L.C.	Gonadotropin releasing hormone antagonists
CN101027318B (zh) *	2004-07-19	2016-05-25	比奥孔有限公司	胰岛素-低聚物共轭物，制剂及其用途
JP4965446B2 (ja) *	2004-08-31	2012-07-04	ノヴォノルディスクアー／エス	ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
EP1674082A1 (de) *	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006102117A1 (en) *	2005-03-17	2006-09-28	Elan Pharma International Limited	Nanoparticulate biphosphonate compositions
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
IL174387A0 (en)	2005-03-31	2008-01-20	Dexcel Pharma Technologies Ltd	A solid composition for intra-oral delivery of insulin
WO2006116565A2 (en)	2005-04-25	2006-11-02	Amgen Inc.	Biodegradable peptide sustained release compositions containing porogens
NZ580951A (en) *	2005-04-29	2011-06-30	Cubist Pharm Inc	Therapeutic compositions
JP2008542235A (ja) *	2005-05-25	2008-11-27	ノボ・ノルデイスク・エー／エス	安定化ポリペプチド製剤
CN101505746A (zh) *	2005-06-17	2009-08-12	迪纳米斯治疗公司	炎症的治疗方法
US20070021378A1 (en) *	2005-07-22	2007-01-25	The Regents Of The University Of California	Heparin compositions and selectin inhibition
US20070077313A1 (en) *	2005-10-04	2007-04-05	U.S. Pharmaceutical Corporation	Toleration iron supplement compositions
BRPI0710503A2 (pt) *	2006-04-07	2011-08-16	Merrion Res Iii Ltd	uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
WO2007146234A2 (en) *	2006-06-09	2007-12-21	Merrion Research Ii Limited	Solid oral dosage form containing an enhancer
US20090004281A1 (en) *	2007-06-26	2009-01-01	Biovail Laboratories International S.R.L.	Multiparticulate osmotic delivery system
CN101125132A (zh)	2007-07-25	2008-02-20	司炳奎	口服胰岛素肠溶胶囊及其制备方法
US20090280169A1 (en)	2008-05-07	2009-11-12	Merrion Research Iii Limited	Compositions of peptides and processes of preparation thereof
RU2678833C2 (ru) *	2008-09-17	2019-02-04	Киазма Инк.	Фармацевтические композиции и соответствующие способы доставки
TWI480286B (zh)	2009-02-25	2015-04-11	Merrion Res Iii Ltd	雙膦酸鹽類組合物及藥物遞送
US9089484B2 (en)	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration

2007
- 2007-04-09 BR BRPI0710503-7A patent/BRPI0710503A2/pt not_active IP Right Cessation
- 2007-04-09 CN CN201510445915.8A patent/CN105232482A/zh active Pending
- 2007-04-09 ES ES07755266T patent/ES2426445T3/es active Active
- 2007-04-09 KR KR1020087027154A patent/KR101191322B1/ko not_active Expired - Fee Related
- 2007-04-09 CN CNA2007800158583A patent/CN101437522A/zh active Pending
- 2007-04-09 US US11/733,007 patent/US7704977B2/en not_active Expired - Fee Related
- 2007-04-09 WO PCT/US2007/008935 patent/WO2007117706A2/en not_active Ceased
- 2007-04-09 CA CA2648594A patent/CA2648594C/en not_active Expired - Fee Related
- 2007-04-09 EP EP12166313A patent/EP2526950A1/en not_active Withdrawn
- 2007-04-09 RU RU2008144136/15A patent/RU2437662C2/ru not_active IP Right Cessation
- 2007-04-09 AU AU2007235251A patent/AU2007235251B2/en not_active Ceased
- 2007-04-09 JP JP2009504354A patent/JP5450052B2/ja not_active Expired - Fee Related
- 2007-04-09 EP EP07755266.9A patent/EP2007397B1/en not_active Not-in-force
- 2007-04-09 MX MX2008012678A patent/MX2008012678A/es active IP Right Grant
2008
- 2008-09-22 IL IL194277A patent/IL194277A/en not_active IP Right Cessation
2009
- 2009-06-10 US US12/481,952 patent/US8883201B2/en not_active Expired - Fee Related
2010
- 2010-04-26 US US12/767,076 patent/US8883203B2/en not_active Expired - Fee Related
2013
- 2013-08-16 JP JP2013169062A patent/JP2014037412A/ja active Pending
2015
- 2015-10-19 JP JP2015205201A patent/JP2016040301A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20090037851A (ko)	2009-04-16
RU2008144136A (ru)	2010-05-20
US7704977B2 (en)	2010-04-27
KR101191322B1 (ko)	2012-10-16
AU2007235251B2 (en)	2013-02-07
JP2016040301A (ja)	2016-03-24
US8883201B2 (en)	2014-11-11
CN105232482A (zh)	2016-01-13
JP5450052B2 (ja)	2014-03-26
WO2007117706A3 (en)	2008-10-16
EP2007397B1 (en)	2013-07-24
JP2009533349A (ja)	2009-09-17
EP2007397A4 (en)	2010-03-10
IL194277A0 (en)	2009-09-22
EP2007397A2 (en)	2008-12-31
US20100247640A1 (en)	2010-09-30
CA2648594A1 (en)	2007-10-18
US20100022480A1 (en)	2010-01-28
CN101437522A (zh)	2009-05-20
JP2014037412A (ja)	2014-02-27
CA2648594C (en)	2012-10-16
AU2007235251A2 (en)	2008-11-06
BRPI0710503A2 (pt)	2011-08-16
US8883203B2 (en)	2014-11-11
US20070238707A1 (en)	2007-10-11
IL194277A (en)	2014-01-30
WO2007117706A2 (en)	2007-10-18
EP2526950A1 (en)	2012-11-28
AU2007235251A1 (en)	2007-10-18
MX2008012678A (es)	2008-12-17
RU2437662C2 (ru)	2011-12-27

Publication	Publication Date	Title
EP2007397B1 (en)	2013-07-24	Solid oral dosage form containing an enhancer
US8119159B2 (en)	2012-02-21	Solid oral dosage form containing an enhancer
ES2301477T3 (es)	2008-07-01	Forma de dosificacion oral solida que contiene un potenciador.
US8053429B2 (en)	2011-11-08	Solid oral dosage form containing an enhancer
JP2009539862A (ja)	2009-11-19	強化剤を含む固体経口投与剤形
ES2774962T3 (es)	2020-07-23	Productos farmacéuticos de administración oral
JP4599714B2 (ja)	2010-12-15	経口吸収改善医薬用組成物
AU2013205707A1 (en)	2013-05-23	Solid oral dosage form containing an enhancer